ArticleBMC cardiovascular disorders2025
Effects of trimetazidine on oxidant-antioxidant balance and angiogenesis; an in vivo experimental study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potential Mechanisms of Trimetazidine and Coenzyme Q10 Against Antipsychotic-Induced Myocarditis: A Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Study.CNS neuroscience & therapeutics · 2026Article
- Redox Imbalance and Coronary Complexity Linking Oxidative Stress Biomarkers to SYNTAX II Score in Acute Coronary Syndrome.Biomedicines · 2026Article
- DICAR/DICAR-JP exerts therapeutic effects in brain stroke via the miR-361-5p/PRMT1 pathway.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe evaluated the effects of trimetazidine (TMZ) on the oxidative-antioxidative balance and angiogenesis in an in vivo experimental model. This study aims to evaluate the effects of trimetazidine on angiogenesis through histological analysis and to assess its impact on oxidative-antioxidative balance through biochemical measurements.
methodsIn this study, Ross 308 breed chicken eggs (n = 40) were used, and embryos were divided into four distinct groups. On the eighth day of incubation, the vascular density of the embryos was examined. Following the assessment of vascular development, 4-5 mL of albumin was collected via syringe to measure oxidative stress markers. Each group consisted of 10 embryos, with a total of 40 embryos used in the study. The groups were organized as follows: Control Group (CG), Bevacizumab Group (BC), Trimetazidine 10⁻⁴ Group, and Trimetazidine 10⁻⁵ Group.
resultsWhen the total oxidative capacity (TOC) levels were compared among the groups, the bevacizumab group exhibited significantly higher values than the control group (p < 0.05). In oxidative stress index (OSI) measurements, the bevacizumab group also showed significantly higher values compared to the control group (p < 0.05). In contrast, when the total antioxidant capacity (TAC) levels were compared, both the Trimetazidine 10⁻⁴ and Trimetazidine 10⁻⁵ groups demonstrated significantly higher values than the control group (p < 0.05). Regarding angiogenesis scoring, the bevacizumab group exhibited a significant anti-angiogenic effect compared to the control group. However, no statistically significant difference was observed between the Trimetazidine 10⁻⁴ and Trimetazidine 10⁻⁵ groups and the control group (p > 0.05).
conclusionTrimetazidine demonstrated significant antioxidant activity in an in vivo Chorioallantoic Membrane (CAM) model at both 10⁻⁴ M and 10⁻⁵ M concentrations. However, no positive or negative effects on angiogenesis were detected. We believe that the real-time observation of angiogenesis in our study provided significant value to our research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.